On Tuesday, Shares of Boyd Gaming Corporation (NYSE:BYD), lost -2.77% to $15.10.
Offering an elevated yet casual dining experience, The Spotted Horse Tavern and Dining Parlor has made its debut at Evangeline Downs Racetrack Casino Hotel.
“The Spotted Horse is a dining experience unlike anything else in this region,” said Ted Bogich, Senior Vice President of Operations for Boyd Gaming (BYD), owner and operator of Evangeline Downs. “With modern takes on traditional Louisiana flavors, offered in a beautifully designed and whimsical setting, the Spotted Horse gives customers another great reason to visit Evangeline Downs.”
Inspired by an urban legend of a “long-necked spotted horse” (i.e., a giraffe) winning the race by a neck, the restaurant’s flair for the fantastic is reflected throughout the new space. The multi-faceted experience features a tavern on one side, perfect for sipping a local brew and enjoying down-home cuisine; and a full-service restaurant on the other.
Boyd Gaming Corporation, together with its auxiliaries, operates as a multi-jurisdictional gaming company. It operates in five segments: Las Vegas, Downtown Las Vegas, Midwest and South, Peninsula, and Borgata.
Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), declined -5.09% to $31.90, during its last trading session.
Sarepta Therapeutics, declared that Edward Kaye, MD, Sarepta’s interim chief executive officer and chief medical officer will provide a corporate update and report on recent data from the Phase IIb study of eteplirsen for Duchenne muscular dystrophy via a live webcast and conference call on October 1, 2015 at 7:00 AM EST. The update will be followed by a panel negotiation with Duchenne muscular dystrophy experts Anne Connolly, MD; Eugenio Mercuri, MD, PhD; Jerry Mendell, MD; Perry Shieh, MD, PhD; and Steve Wilton, PhD, BSc.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin.
At the end of Tuesday’s trade, Shares of Monster Worldwide, Inc. (NYSE:MWW), gained 2.40% to $6.41.
Monster Worldwide, declared that it has reached a contract to sell its 50.01% ownership position in its South Korean operation, JobKorea, to H&Q Korea for about $85 million. The transaction is predictable to close in October 2015. In December 2013, H&Q Korea attained 49.99% of JobKorea from Monster and since that time the two companies have worked in partnership in managing the business. The sale of Monster’s remaining stake in the operation is compriseent with Monster’s continued strategy of unlocking value and sharpening its focus on its core online recruitment platform.
Tim Yates, President and Chief Executive Officer of Monster, said, “This transaction reflects our commitment to our strategy of focusing on our core value proposition while also demonstrating the underlying value of Monster’s global enterprise. We have enjoyed our ten year relationship with the administration and operating team at JobKorea and our two year partnership with H&Q Korea. We wish them well as they build on their leading position in Korea’s online recruitment market and look forward to the opportunity to continue working together through our international cross-selling arrangement. The proceeds from this transaction will provide added financial flexibility as we move forward toward our objective of enhancing shareholder returns as part of our capital allocation program.”
Monster Worldwide, Inc., together with its auxiliaries, provides online and mobile employment solutions worldwide. The company operates in three segments: Careers-North America, Careers-International, and Internet Advertising & Fees. Its services and solutions comprise searchable job advertisements; resume database access; recruitment media solutions through its advertising network and partnerships; Twitter Cards and social job distribution; social profile aggregation; and other career-related content.
Finally, Intra-Cellular Therapies Inc (NASDAQ:ITCI), ended its last trade with 1.24% gain, and closed at $37.50.
Intra-Cellular Therapies, declared the completion of its formerly declared underwritten public offering of 6,900,000 shares of its common stock at a public offering price of $43.50 per share. In addition, the underwriters have exercised an option to purchase an additional 1,035,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.
All of the shares in the offering were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular of about $345 million and net proceeds of about $327.4 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Leerink Partners LLC, Cowen and Company, LLC, RBC Capital Markets, LLC and Guggenheim Securities, LLC acted as joint book-running managers for the offering. Ladenburg Thalmann & Co. Inc. and SunTrust Robinson Humphrey, Inc. acted as co-managers for the offering.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system (CNS).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
